This growth was bolstered by strategic product launches such as the enVista NV intraocular lens, Blink NutriTears, and Bausch + Lomb INFUSE contact lenses. In light of these results, the company ...

This growth was bolstered by strategic product launches such as the enVista NV intraocular lens, Blink NutriTears, and Bausch + Lomb INFUSE contact lenses. In light of these results, the company ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent ...

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the ...